Stay updated on Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial
Sign up to get notified when there's something new on the Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial page.

Latest updates to the Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe trial record displays its study details, including eligibility criteria, treatment plan, outcomes, and study dates. It identifies the study as terminated and no longer recruiting.SummaryDifference59%

- Check20 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the study record remains inaccessible behind a 403 error.SummaryDifference0.2%

- Check27 days agoChange DetectedA banner announces NIH website transition updates and states that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe site revision in the footer changed from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study record page now shows a 403 Forbidden error, replacing the detailed study content with a generic error page. This indicates that access to the core trial information is blocked.SummaryDifference20%

Stay in the know with updates to Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Re-sensitizing Carboplatin-Resistant Ovarian Cancer: FAK Clinical Trial page.